Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade during Percutaneous Coronary intervention: REPLACE-2 Randomized Trial
- A. Michael Lincoff*
- , John A. Bittl
- , Robert A. Harrington
- , Frederick Feit
- , Neal S. Kleiman
- , J. Daniel Jackman
- , Ian J. Sarembock
- , David J. Cohen
- , Douglas Spriggs
- , Ramin Ebrahimi
- , Gadi Keren
- , Jeffrey Carr
- , Eric A. Cohen
- , Amadeo Betriu
- , Walter Desmet
- , Dean J. Kereiakes
- , Wolfgang Rutsch
- , Robert G. Wilcox
- , Pim J. De Feyter
- , Alec Vahanian
*Corresponding author for this work
- Cleveland Clinic Foundation
- Munroe Regional Medical Center
- Duke University
- New York University
- Houston Methodist
- University of Virginia
- Beth Israel Deaconess Medical Center
- Clearwater Cardiovascular Consultants
- Department of Veterans Affairs
- Tel Aviv Sourasky Medical Center
- Texas Medical Center
- University of Toronto
- Hospital Clinic Barcelona
- KU Leuven
- Health Alliance
- Charité – Universitätsmedizin Berlin
- Nottingham University Hospitals NHS Trust
- Erasmus University Rotterdam
- Université Paris Cité
Research output: Contribution to journal › Article › peer-review
1163
Scopus
citations